Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The Central Drugs Standard Control Organization (CDSCO) has cancelled the import registration certificate of a cosmetic peel product due to non-compliance with prescribed pH tolerance limits and labelling requirements, including a “patient use” claim that did not conform to applicable Indian cosmetic labelling standards. The action reflects increased regulatory scrutiny of cosmetic product safety and labelling in India.
Source: shortlink.uk/1uZtd

2. A Parliamentary panel has recommended that the Central Drugs Standard Control Organisation (CDSCO) establish a uniform regulatory framework to address misleading advertisements relating to Ayush products, noting that the existing mechanism may result in inconsistent handling of complaints across States. The panel further observed that the absence of a standardized timeline and monitoring framework for disposal of complaints could undermine the effectiveness of the complaint reporting mechanism and potentially discourage citizens from reporting such violations.
Source: shortlink.uk/1uZth

3. The Ministry of Electronics and Information Technology has launched the Intellectual Property Catalyst initiative and digital platform to accelerate commercialization of innovations in electronics and information technology. The initiative will support patent filing, technology transfer, licensing, and industry collaboration, while enabling startups and enterprises to access indigenous technologies developed through publicly funded research.
Source: shortlink.uk/1pDUl

4. The Indian government is reportedly considering measures to regulate rising healthcare costs in private hospitals, including capping doctor consultation fees and hospital billing margins through amendments to the Clinical Establishments Act, 2010. The move aims to standardize private healthcare costs, enhance transparency, and prevent overcharging, while balancing regulatory oversight with professional autonomy in medical practice.
Source: shortlink.uk/1uZtk

5. The US Food and Drug Administration (USFDA) is reportedly exploring regulatory pathways to support the repurposing of older approved drugs for new therapeutic indications, with the aim of accelerating patient access to treatments while reducing development timelines and costs. USFDA said it is focusing on three categories of drug candidates: those with existing data supporting new uses, those showing early clinical promise, and those backed by preclinical or AI/ML-generated findings. FDA is seeking public input from patients, clinicians, public health officials, and researchers regarding priority disease areas and potential drugs for repurposing.
Source: shortlink.uk/1pDUo

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The Government of India is considering capping billing margins charged by private hospitals on medical devices to curb overcharging and reduce treatment costs. This is important as excessive markups increase patient expenses and insurance premiums. If implemented, it will limit hospital margins, improving pricing transparency and affordability.
Source: shortlink.uk/1olUB

2. The Central Government has established the Online Gaming Authority of India (OGAI), with effect from May 1, 2026, under the Promotion and Regulation of Online Gaming Act, 2025, to regulate the gaming sector. Operating under MeitY, this multi-sectoral authority will oversee licensing, mandate registration for esports, and enforce stringent compliance requirements, with a view to enhancing user safety and strengthening regulatory oversight of online gaming.
Source: shortlink.uk/1tDQe

3. Indias central drug ministry has proposed amendment to Drugs Rules 1945 by expanding the list of licences that may be exempted from requiring a Form 29 licence for manufacturing of drugs for test or analysis. The amendment proposes to include Forms 25A (loan licences), 25F (Schedule X drugs), 28A/28B (Schedule C, C(1), and X drugs), 28D/28DA (vaccines, sera, r-DNA drugs), and 28F (umbilical cord blood stem cells). Objections and suggestions from the industry will be considered for thirty days.
Source: shortlink.uk/1tDQk

4. The Delhi High Court has restrained the use of the trademark “MARQ,” finding it deceptively similar to “MARC” and likely to confuse consumers. This reinforces trademark protection by emphasizing that minor spelling differences, use of house marks, or later registrations do not override prior rights and established goodwill.
Source: shortlink.uk/1tDQs

5. Government of India plans a Health Claims Index to transparency and standardize pricing in India health insurance sector. Using anonymized data from the National Health Claims Exchange, it will benchmark claims timelines, approvals and costs, enabling underwriting, reducing inefficiencies, and supporting informed consumer decisions, subject to scale and execution.
Source: shortlink.uk/1olUW

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The Delhi High Court granted interim relief to Pharmaceutical company by restraining other pharmaceutical company from using “ALKAKIND” or similar marks. The Court held that the “KIND” suffix has acquired distinctiveness through extensive use, creating a strong likelihood of consumer confusion and reinforcing trademark protection for established pharma brands.
Source: shortlink.uk/1n47Q

2. The Government of India has issued the Safety of Household, Commercial and Similar Electrical Appliances (Quality Control) Order, 2026, making BIS certification mandatory for 90 categories of electrical appliances. It will come into force on 1 October 2026, with phased timelines for MSMEs. Non-compliance will attract penalties under the BIS Act, 2016.
Source: shortlink.uk/1n48h

3. Indian pharma manufacturers have reportedly urged the National Pharmaceutical Pricing Authority of India to approve up to a 50% price increase for platinum-based chemotherapy drugs such as carboplatin, cisplatin, and oxaliplatin, after platinum prices nearly doubled from ₹3,869 to ₹8,000 per gram in six months, making production financially unviable and risking supply disruptions.
Source: shortlink.uk/1n48q

4. The Drug Technical Advisory Board (DTAB) has proposed extending PSUR timelines under the New Drugs and Clinical Trials Rules, 2019 for modified or sustained release drugs, novel drug delivery systems, and advanced biologics across their lifecycle, with annual and triennial reporting beyond four years. Currently, PSURs are submitted semi-annually for two years and annually thereafter.
Source: shortlink.uk/1sisG

5. India’s affordable generic medicines under the Jan Aushadhi scheme may see price increases as shipping disruptions linked to the West Asia conflict have raised raw material costs and constrained supply. The supply crunch is affecting local manufacturing, with smaller pharma units facing margin pressure, potentially impacting availability of low-cost medicines across Jan Aushadhi Kendras.
Source: shortlink.uk/1n48A

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. we hope you enjoy reading it.

1. India’s central drug regulator (CDSCO)has issued a Subject Expert Committees (SEC) guidance document 2025, which outlines a structured process for evaluating clinical trial and new drug applications. It covers SEC composition, review timelines, quorum, waiver criteria, applicant obligations, and decision protocols to ensure scientific rigor, transparency, and regulatory consistency.
Source: bit.ly/4f2ICpE

2. The Central Pollution Control Board has extended the timeline for filing quarterly and annual E Waste returns for the financial year 2024–25 from June 30, 2025 to August 15, 2025. All registered entities must submit return via the E Waste EPR Portal to avoid penalties under the Environment Protection Act, 1986.
Source: bit.ly/44V6tCM

3. India’s Bureau of Energy Efficiency has issued the Draft Appliance Labelling Regulations, 2025, alongside a repeal order for thirteen earlier label-display regulations affecting appliances like refrigerators, ACs, TVs, washing machines, transformers, lamps, and fans. Stakeholder feedback is invited until August 10, 2025.
Source: bit.ly/4f7if1F

4. The Government of India is being urged by experts and the Thalassemia Patients Advocacy Group (TPAG) to mandate Nucleic Acid Testing (NAT) in all blood banks to detect HIV, Hepatitis B, and C during the early “window period.” The call highlights existing gaps in blood safety, with demands for Ministry of Health action amid rising concerns over patient rights and transfusion-linked infections.
Source: bit.ly/3GXeQpo

5. Advisory panel of US Food and Drug Administration has reportedly recommended removing the strong black box warning from vaginal estrogen products, saying it’s based on outdated data that scares women and doctors. Experts highlighted benefits like heart attack and bone fracture prevention. The FDA has yet to make a final decision.
Source: bit.ly/44DSh2j